Boston Scientific Reports Higher Revenue, Operating Income, and Diluted EPS on Both Quarterly and Year-to-Date Views in Form Filing

Bottom line

For period-ended-2026-06-30, BOSTON SCIENTIFIC CORP (ticker BSX, CIK 0000885725, accession 0000885725-26-000053, filed on 10-Q) reported a clean, top-line-and-bottom-line growth pattern across both the three-month and six-month year-to-date reporting windows. The bottom line moved higher on both views: Earnings Per Share, Diluted for the three months ended June 30, 2026 was $0.61 per diluted share USD/SHARES, above the prior-year the three months ended June 30, 2025 level of $0.53 per diluted share USD/SHARES, and Earnings Per Share, Diluted for the six months ended June 30, 2026 was $1.51 per diluted share USD/SHARES, above the prior-year the six months ended June 30, 2025 level of $0.98 per diluted share USD/SHARES, with both transitions staying in profit territory. Operating Income (Loss) tracked the same shape: $1,178,000,000 USD for the three months ended June 30, 2026 versus $819,000,000 USD for the three months ended June 30, 2025, and $2,279,000,000 USD for the six months ended June 30, 2026 versus $1,740,000,000 USD for the six months ended June 30, 2025, again profit on both sides of each comparison. Revenue from Contract with Customer, Excluding Assessed Tax likewise rose on both windows: $5,442,000,000 USD for the three months ended June 30, 2026 versus $5,061,000,000 USD for the three months ended June 30, 2025, and $10,646,000,000 USD for the six months ended June 30, 2026 versus $9,724,000,000 USD for the six months ended June 30, 2025. The consolidated picture, then, is higher revenue paired with higher operating income and higher diluted EPS across the quarter and the year-to-date period, and no margin or earnings metric reported here flipped sign versus the prior year.

The filing's accompanying notes present these results inside a standard forward-looking-statements framework, flagging risks such as foreign-currency fluctuations, trade and tariff policy changes, geopolitical tensions, supply-chain disruptions, cybersecurity and public-health events, labor cost trends, clinical-trial outcomes, product launches and acceptance, competitive pricing, procedural volumes, acquisitions and integration, intellectual property, litigation, financial-market conditions, restructuring programs, and execution of the company's cost-savings and growth initiatives. Management did not, in the cited passage, attribute the period's higher revenue, operating income, or diluted EPS to any single driver.

On the available evidence, the three growth comparisons reported here — revenue, operating income, and diluted EPS, each on both the quarter and the six-month year-to-date view — are directionally aligned and reinforce one another rather than diverging.

None visible in the cited passages for these specific line items; the statement that all six comparisons rose is the only direction the filing evidence supports.

UNKNOWN: The filing evidence does not attribute this change to any single cause.

Financial performance

Reported facts

The filing covers the three-month reporting period and the six-month year-to-date period for BOSTON SCIENTIFIC CORP (BSX), submitted on 10-Q under accession 0000885725-26-000053 with CIK 0000885725 for period-ended-2026-06-30.

- Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended June 30, 2026 was $5,442,000,000 USD, higher than the prior-year comparative of $5,061,000,000 USD for the three months ended June 30, 2025. - Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was $10,646,000,000 USD, higher than the prior-year comparative of $9,724,000,000 USD for the six months ended June 30, 2025. - Operating Income (Loss) for the three months ended June 30, 2026 was $1,178,000,000 USD, higher than the prior-year comparative of $819,000,000 USD for the three months ended June 30, 2025. - Operating Income (Loss) for the six months ended June 30, 2026 was $2,279,000,000 USD, higher than the prior-year comparative of $1,740,000,000 USD for the six months ended June 30, 2025. - Earnings Per Share, Diluted for the three months ended June 30, 2026 was $0.61 per diluted share USD/SHARES, higher than the prior-year comparative of $0.53 per diluted share USD/SHARES for the three months ended June 30, 2025. - Earnings Per Share, Diluted for the six months ended June 30, 2026 was $1.51 per diluted share USD/SHARES, higher than the prior-year comparative of $0.98 per diluted share USD/SHARES for the six months ended June 30, 2025. - All three dimensions — revenue, operating income, and diluted EPS — remained profit-to-profit on both the quarter and the year-to-date views.

Management explanations

- The unaudited consolidated financial statements were prepared in accordance with GAAP and the instructions to 10-Q, and should be read alongside the audited statements in Item 8 of the most recent Annual Report. - Interim results for the three months ended June 30, 2026 and the six months ended June 30, 2026 are not necessarily indicative of full-year outcomes. - Amounts are reported in millions and computed from thousands, so the sum of components may not equal the total due to rounding; certain columns and rows within tables may not add due to the use of rounded numbers. - The Company consolidates its majority stake in Acotec Scientific Holdings Limited on a one-quarter lag. - Acquired entities are included from their respective acquisition dates; supplemental pro forma information for completed acquisitions or divestitures is not presented because the results are not material. - Contingent consideration is measured using Level 3 fair value measurements.

Analyst inference

- The synchronized higher direction across revenue, operating income, and diluted EPS on both views implies top-line growth flowing through to earnings without an operating-loss-to-profit transition in any of the three dimensions. - Because the quarter and year-to-date periods both report profit-to-profit comparisons for revenue, operating income, and diluted EPS, the directional change on the year-to-date view is consistent with the directional change on the quarterly view, rather than a divergent pattern. - The reference to Acotec being consolidated on a one-quarter lag means the year-to-date period reflects that lag, while the quarterly view reflects a different cut of the Acotec contribution; segment-level detail is not separately disclosed in the filing evidence.

Counter-evidence and unknowns

- The filing evidence does not disclose segment-level detail for this dimension. The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute the year-over-year change in any of the three reported dimensions to any single cause. The filing evidence does not attribute this change to any single cause. - No forward-looking guidance figures, target prices, or quantified outlook statements are contained in the cited section of the filing; the cautionary language enumerates broad risk categories rather than numeric expectations.

The pattern of higher revenue, higher operating income, and higher diluted EPS on both the quarterly and the six-month year-to-date views is shared with several other interim filings, including Ares Management's Interim Filing Shows Higher Revenue and Higher Profit on Both Quarter and Year-to-Date Views, though the underlying drivers disclosed in each filing differ.

Operating drivers and segments

the filing does not break out segment-level revenue or operating income for BOSTON SCIENTIFIC CORP in the evidence available to this section; no division, geography, or product-line reconciliation is reproduced in the quoted source narrative. As a result, segment drivers can only be discussed at the consolidated top line. Revenue from Contract with Customer, Excluding Assessed Tax was $10,646,000,000 USD for the six-month year-to-date period the six months ended June 30, 2026, compared with $9,724,000,000 USD for the prior-year six-month comparative the six months ended June 30, 2025 — authorized direction increase. For the three-month view, revenue was $5,442,000,000 USD for the three months ended June 30, 2026 against $5,061,000,000 USD for the three months ended June 30, 2025 — authorized direction increase. Operating Income (Loss) was $2,279,000,000 USD for the six months ended June 30, 2026 versus $1,740,000,000 USD for the six months ended June 30, 2025 — authorized direction increase, profit to profit. The three-month operating result was $1,178,000,000 USD for the three months ended June 30, 2026 versus $819,000,000 USD for the three months ended June 30, 2025 — authorized direction increase, profit to profit. Because segment splits are absent, no individual business can be credited with, or blamed for, the consolidated movement.

The narrative reproduces the cautionary forward-looking statement rather than a per-segment commentary. Management frames future performance as contingent on the risk factors described in Item 1A of the most recent Annual Report, plus additional cautionary language covering foreign-currency fluctuations, trade and tariff policy, geopolitical conditions, manufacturing and supply-chain disruption, cybersecurity events, public health and climate-related disruptions, labor shortages and cost increases, clinical-trial and market-study outcomes, new product introductions and acceptance, competition, expected pricing, expected procedural volumes, acquisitions and their integration, demographic trends, intellectual property, litigation, financial-market conditions, restructuring program execution, cost-savings and growth initiatives, sustainability goal attainment, and the decisions of the Company and its competitors. Operating results for the three and six months ended in June are explicitly noted in NOTE A as not necessarily indicative of the full-year results. No quantified explanation of the period-over-period revenue or operating-income change is offered in the text. The contingent consideration liability is addressed through fair-value measurements referenced at Level 3, but again without a quantified driver attribution.

Because no quantified bridge or driver narrative is provided for the top-line or operating-income change in the filing evidence, no analyst-style decomposition can be reconstructed here. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

For readers comparing this report with other interim filings, a useful peer-set data point is SMITH A O CORP (AOS) Reports Softer Revenue, Operating Income, Net Income, and Diluted EPS on Both the Quarter and Six-Month Year-to-Date Views in Form (Accession, which illustrates the opposite directional pattern on the same revenue and operating-income lines that BOSTON SCIENTIFIC CORP reports here as authorized-direction increases.

Cash flow and capital

- Operating cash generation in the six-month year-to-date period reported by BOSTON SCIENTIFIC CORP in its 10-Q for period-ended-2026-06-30 (accession 0000885725-26-000053) came in at $1,822,000,000 USD, compared with $1,827,000,000 USD in the prior-year comparative, a year-over-year decline. - Cash used in investing activities widened to -$2,547,000,000 USD for the six months ended June 30, 2026, versus -$1,626,000,000 USD for the six months ended June 30, 2025. - Cash used in financing activities was -$670,000,000 USD for the six months ended June 30, 2026, compared with -$107,000,000 USD for the six months ended June 30, 2025, also a larger outflow than the prior year.

- Capital spending of $372,000,000 USD for the six months ended June 30, 2026 was higher than the $344,000,000 USD recorded for the six months ended June 30, 2025. - Share repurchases rose to $2,000,000,000 USD for the six months ended June 30, 2026 versus $0 USD for the six months ended June 30, 2025, marking a return to buyback activity after a prior-year reading reported as zero. - On the balance sheet at the balance sheet date of June 30, 2026, cash and equivalents stood at $539,000,000 USD, accounts receivable (gross of allowance for credit loss) at $3,184,000,000 USD, and accounts payable at $1,231,000,000 USD.

- The investing cash outflow directionally reflects the recent deal activity summarized in Note B: acquisitions completed in the first six months of the year, the announced Scivita Medical transaction expected to close during the third quarter, the ongoing FTC Second Request review of the Penumbra transaction, and the Nalu Medical acquisition, whose preliminary purchase price allocation is presented in the filing. The cited note also flags contingent consideration fair value measured at the lower fair-value tier disclosed under Level 3.

The filing notes risk-factor context drawn from Item 1A and the basis-of-presentation reference under Item 8, but does not quantify deal-driven investing cash usage by target. - The filing evidence does not attribute this change to any single cause. - Free cash flow, defined as operating cash flow less capital expenditures, is not directly reported in the evidence supplied; with operating cash down and capex up year over year, the gap would be expected to narrow directionally, though the magnitude cannot be inferred.

- Liquidity at the balance sheet date of June 30, 2026 is supported by the cash and equivalents balance and a working-capital position in which accounts receivable (gross) exceeded accounts payable by a meaningful amount; the filing does not provide a current ratio. - Net debt position, leverage ratios, dividends paid, and any debt issuance or repayment detail are not present in the evidence supplied for this section, and segment-level free-cash-flow disclosure is not provided, so The filing evidence does not disclose segment-level detail for this dimension.

applies to any segment-cut view. - The filing evidence contains no peer or industry comparison. - For comparison, Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in the reporting period Filing illustrates a contrasting capital-allocation profile where operating cash strength supported different year-over-year dynamics than those implied here, where higher capex and higher buybacks coincided with weaker operating cash.

Peer and historical context

- Because the filing does not name peer issuers or industry indices, a like-for-like benchmark cannot be drawn from the filing evidence; any peer framing must come from outside sources and so is left out here. - The only historical benchmark available is the company's own prior-year comparatives reported in the same interim document, which permits a sequential read of growth or contraction across the six-month year-to-date and the three-month reporting period. - The interim document carries no peer table, no industry composite, and no management commentary benchmarking performance against other medical device issuers, so any cross-company narrative is unsupported by the filing evidence. - Operating cash flow is reported as a positive figure in both the current and the prior-year year-to-date periods, but no narrative in the filing explains the direction of that movement; an interpretive gap therefore remains. <prose> Reported facts

For BOSTON SCIENTIFIC CORP (BSX) on 10-Q covering period-ended-2026-06-30, filed under accession 0000885725-26-000053, the only historical comparator disclosed in the interim document is the company's own prior-year figures. Revenue from Contract with Customer, Excluding Assessed Tax was $5,442,000,000 USD for the three months ended June 30, 2026 and $5,061,000,000 USD for the three months ended June 30, 2025, and the same line item was $10,646,000,000 USD for the six months ended June 30, 2026 against $9,724,000,000 USD for the six months ended June 30, 2025. Operating Income (Loss) was $1,178,000,000 USD for the three months ended June 30, 2026 versus $819,000,000 USD for the three months ended June 30, 2025, and $2,279,000,000 USD for the six months ended June 30, 2026 versus $1,740,000,000 USD for the six months ended June 30, 2025. Net Cash Provided by (Used in) Operating Activities was $1,822,000,000 USD for the six months ended June 30, 2026 and $1,827,000,000 USD for the six months ended June 30, 2025.

Management explanations

The interim filing does not include a management discussion of comparative performance in this section of the quoted record. Acquisition activity described in the surrounding narrative — covering Penumbra, Nalu Medical, SoniVie, Bolt Medical and Cortex, together with the smaller bolt-on transactions completed during the first six months of the year — is presented as factual description rather than as a quantified year-over-year commentary, and is not used here as a substitute for a peer or historical comparison. Cross-references to Item 1A and Item 8 point readers to the most recent Annual Report on Form referenced elsewhere in the filing, but neither cited note supplies a peer benchmark or a multi-year time series.

Analyst inference

Because the only prior-period values available are those reproduced above, the historical read is restricted to the current interim versus the prior-year interim on both the quarter and the six-month year-to-date views. Revenue is positive in every period shown, operating income is positive in every period shown, and operating cash flow is positive in both year-to-date periods, so the directional set is internally consistent across the two views. The absence of any management narrative on those movements means the reader cannot, from this filing alone, separate organic growth from acquisition contribution, currency effects from pricing, or mix from volume.

Counter-evidence

The filing evidence contains no peer or industry comparison. The filing evidence does not attribute this change to any single cause.

A broader context for the reported figures can be found alongside other interim filings in the Finance Calculators Insights section, where peer issuers such as A. O. Smith and AES Corp have already published their own quarter and six-month year-to-date views for adjacent periods.

Scenario analysis

The base case assumes that recent revenue momentum carries into the second half of the fiscal year without material disruption. Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period is positive and is higher than the prior-year comparative, and the six-month year-to-date revenue is also positive and higher than the prior-year comparative. $5,442,000,000 and $5,061,000,000 capture the quarter view, while $10,646,000,000 and $9,724,000,000 frame the year-to-date view. Operating Income (Loss) is a profit in both periods and is higher on both the three-month and the six-month comparisons. Earnings Per Share, Diluted is a profit in both periods and is higher on both comparisons. Cash used in investing activities is negative in both periods and decreased in the half-year comparison, while cash provided by operating activities is positive in both periods and decreased. Payments to acquire property, plant, and equipment rose, and Payments for Repurchase of Common Stock are positive in the current half-year versus zero in the prior half-year. Acquisition activity from the cited note, including Nalu Medical, SoniVie, Bolt Medical, and Cortex, continues to consume cash for upfront payments tied to regulatory and revenue milestones, with fair value supported by the multi-period excess earnings method as referenced in the cited note.

The upside case layers in stronger-than-modeled conversion of acquired technologies and milestone achievements on contingent consideration. Contingent consideration obligations referenced at the lower fair-value tier under Level 3 could decline if regulatory and revenue-based milestones are deferred or repriced downward, freeing future cash. Continued top-line growth at the trajectory implied by the current quarter and year-to-date revenue figures would compound the higher-than-prior-period baseline. Capital allocation discipline, reflected in repurchases restarting from a zero prior-year base, could return capital to shareholders while still funding strategic investments such as the MiRus LLC investment noted in the cited note.

The downside case contemplates slower conversion of acquired pipelines, higher contingent consideration payouts as clinical, regulatory, and revenue milestones are met, and pressure on operating cash. Strategic investments that are privately held equity securities measured under the measurement alternative could see observable price changes that flow through Other, net, and any softening of the cardiovascular franchises discussed under Item 1A could weigh on the top line. The filing evidence does not attribute this change to any single cause. Higher contingent consideration assumptions would directly increase the liability referenced in the cited note, while a larger portion of the transaction price for remaining-stake acquisitions becoming payable would reduce investing flexibility given that net cash used in investing already decreased on the half-year view. The cited note also flags goodwill and amortizable intangible values tied to synergies and projected cash flows that are not deductible for tax purposes, so any shortfall against those projections could pressure future amortization and impairment testing.

Risks and what to watch

- Risk factors disclosed: Management directs readers to the cited Item in the most recent Annual Report on Form referenced in Item 1A for a full enumeration of risk factors, and to the financial-statement footnotes presented in Item 8 within 10-Q for period-ended-2026-06-30 (accession 0000885725-26-000053) for additional information. The source narrative does not restate those risk factors here. - Contingent-consideration fair-value exposure: The fair-value measurement of the contingent consideration liability, classified within the level referenced as Level 3, reflects projected clinical, regulatory, revenue-based payments and commercialization milestones.

Those projected payments are discounted using a discounted cash flow model, and the disclosed projected year of payment represents the median of the inputs rather than a weighted average. This framing implies that small changes in milestone probability or timing assumptions could move the liability materially, even when the underlying revenue trajectory stays on course. - Acquisition-related intangible amortization: Acquired technology-related and IPR&D intangibles were valued using the multi-period excess earnings method (a form of the income approach) and are amortized on a straight-line basis over their assigned estimated useful lives.

The aggregate transaction price for other acquisitions completed during the first six months of the period referenced by the six months ended June 30, 2026 is disclosed only at an aggregate level, with no segment or geography split provided in the filing evidence. - Strategic-investment measurement risk: Strategic investments are reported within Other investments on the balance sheet and include equity method investments, measurement alternative investments (privately-held equity securities measured at cost less impairment, with adjustments for observable price changes in orderly transactions for identical or similar instruments of the same issuer), and publicly-held equity securities, convertible notes and securities measured at fair value with changes recognized in Other, net within the unaudited consolidated statements of operations.

The valuation reliance on "observable price changes in orderly transactions" introduces judgment risk where orderly transactions for identical or similar instruments are infrequent. S. regulator referenced in the narrative.

Concentration of value in a single privately-held investee increases idiosyncratic exposure relative to a diversified strategic-investment book. - Counter-evidence and unknowns: The filing evidence does not disclose segment-level revenue, geographic revenue mix, or product-line contribution for the three months ended June 30, 2026 or the six months ended June 30, 2026; The filing evidence does not disclose segment-level detail for this dimension.. No peer or industry benchmark is provided in the filing, so any cross-company read (for example, against AES Corp interim filing shows higher revenue and a loss-to-profit swing on net income and diluted EPS or Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year) is external context rather than disclosed comparison; The filing evidence contains no peer or industry comparison..

- Metrics to watch next period: Revenue from Contract with Customer, Excluding Assessed Tax for the prior-year comparative and current year-to-date and quarterly periods referenced by $9,724,000,000, $5,061,000,000, $10,646,000,000, and $5,442,000,000; fair-value movement in the contingent consideration liability classified within the tier referenced in Level 3; further drawdowns or step-ups in measurement alternative investments given the orderly-transaction trigger; and any milestone disclosure tied to the MiRus investment agreement during the back half of the six months ended June 30, 2026.

The filing evidence does not attribute this change to any single cause.